New biosimilar aims to offer cheaper eczema treatment
NCT ID NCT07358156
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial tests a new drug called CKD-706, which is a biosimilar (a close copy) of the approved eczema treatment Dupixent. The study involves 519 healthy adults who will receive a single injection of either CKD-706, the US version of Dupixent, or the European version. Researchers will compare how the drugs move through the body and check for side effects, but this study does not test whether the drug actually improves eczema symptoms.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
CKD-706 (a biosimilar to Dupixent)
What this could lead to
If successful, this could lead to a more affordable treatment option for atopic dermatitis, similar to Dupixent.
What could go wrong
This is an early Phase 1 study in healthy people, not patients. It only tests a single dose, so it cannot show if the drug actually treats the disease. The biosimilar may not work as well as the original.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATOPIC DERMATITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Parexel EPCU Berlin
NOT_YET_RECRUITINGBerlin, State of Berlin, 10115, Germany
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Parexel EPCU London
RECRUITINGLondon, England, HA1 3UJ, United Kingdom
Contact Phone: •••-•••-•••• Email: •••••@•••••